Entities / Company
Supernus Pharmaceuticals (United States).
company in Rockville, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 43
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
FDA approved medications targeting neurological conditions on September 5, 2025, while an aggressive tariff plan caused markets to tank.Some support6 reports2 developments inside
-
Supernus Pharmaceuticals' stock performance lagged market average returns on June 23, 2025, while also riding a major growth wave.Speculative1 report
-
Supernus Pharmaceuticals' ONAPGO is facing competition from AbbVie's pump, while Cantor Fitzgerald makes inquiries into the market for Qelbree.Speculative1 report
-
Sage Therapeutics rejected a takeover offer from Biogen, while Supernus Pharmaceuticals aimed to expand its neuropsychiatric portfolio.Well supported4 reports1 development inside
-
FDA-approved medications targeting neurological conditions discussed alongside investment opportunities for companies like Supernus, Datadog, and Coinbase.Some support1 report
-
Supernus Pharmaceuticals, Bristol-Myers Squibb, and Merck are identified as operating within the branded pharmaceuticals segment.Some support2 reports
-
Supernus Pharmaceuticals shares underperformed the S&P 500 on August 6, 2025, and belongs to the Generic Drugs industry.Some support2 reports
-
Third Avenue Management, an investment firm based in NYC, highlighted Supernus Pharmaceuticals as a stock pick.Some support3 reports
-
The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.Well supported6 reports
-
Jack Khattar became CEO of Supernus Pharmaceuticals, and on August 13, 2025, TD Cowen analysts engaged with the company during its earnings call.Some support1 report
-
Supernus Pharmaceuticals reported that a negative accrual ratio indicated that statutory earnings were less than free cash flow as of August 13, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Supernus Pharmaceuticals (United States) this week
News at the entities that move Supernus Pharmaceuticals (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Supernus Pharmaceuticals (United States)
-
Cantor Fitzgerald OperationalAnalyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Moves Supernus Pharmaceuticals (United States)
-
Bristol-Myers Squibb Mentioned togetherBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves Supernus Pharmaceuticals (United States)
Connections
The 4 strongest of 43, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Sage Therapeutics (United States) Structural
Supernus Pharmaceuticals acquired Sage Therapeutics in a deal worth up to $795 million, establishing a parent-subsidiary relationship.
-
FDA Structural
Supernus Pharmaceuticals relies on the FDA for regulatory approval and oversight of its medications.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald actively monitors Supernus Pharmaceuticals' product performance and issues stock ratings.
-
Bristol-Myers Squibb Mentioned together
Both companies are identified as industry peers operating within the branded pharmaceuticals segment.
History
Events by the month they beganJune 2026
11 events- FDA approved medications targeting neurological conditions on September 5, 2025, while an aggressive tariff plan caused markets to tank.
- Supernus Pharmaceuticals' stock performance lagged market average returns on June 23, 2025, while also riding a major growth wave.
- Supernus Pharmaceuticals' ONAPGO is facing competition from AbbVie's pump, while Cantor Fitzgerald makes inquiries into the market for Qelbree.
- Sage Therapeutics rejected a takeover offer from Biogen, while Supernus Pharmaceuticals aimed to expand its neuropsychiatric portfolio.
- FDA-approved medications targeting neurological conditions discussed alongside investment opportunities for companies like Supernus, Datadog, and Coinbase.
- Supernus Pharmaceuticals, Bristol-Myers Squibb, and Merck are identified as operating within the branded pharmaceuticals segment.
- Supernus Pharmaceuticals shares underperformed the S&P 500 on August 6, 2025, and belongs to the Generic Drugs industry.
- Third Avenue Management, an investment firm based in NYC, highlighted Supernus Pharmaceuticals as a stock pick.
- The acquisition of Sage Therapeutics is anticipated to drive future growth for Supernus Pharmaceuticals.
- Jack Khattar became CEO of Supernus Pharmaceuticals, and on August 13, 2025, TD Cowen analysts engaged with the company during its earnings call.
- Supernus Pharmaceuticals reported that a negative accrual ratio indicated that statutory earnings were less than free cash flow as of August 13, 2025.